TWI372152B - Novel peptide compounds - Google Patents

Novel peptide compounds

Info

Publication number
TWI372152B
TWI372152B TW095144507A TW95144507A TWI372152B TW I372152 B TWI372152 B TW I372152B TW 095144507 A TW095144507 A TW 095144507A TW 95144507 A TW95144507 A TW 95144507A TW I372152 B TWI372152 B TW I372152B
Authority
TW
Taiwan
Prior art keywords
peptide compounds
novel peptide
novel
compounds
peptide
Prior art date
Application number
TW095144507A
Other languages
English (en)
Other versions
TW200730540A (en
Inventor
Toshio Nishihara
Masashi Gotoh
Original Assignee
Int Inst Cancer Immunology Inc
Chugai Pharmaceutical Co Ltd
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc, Chugai Pharmaceutical Co Ltd, Dainippon Sumitomo Pharma Co filed Critical Int Inst Cancer Immunology Inc
Publication of TW200730540A publication Critical patent/TW200730540A/zh
Application granted granted Critical
Publication of TWI372152B publication Critical patent/TWI372152B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001152Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153Wilms tumor 1 [WT1]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW095144507A 2005-11-30 2006-11-30 Novel peptide compounds TWI372152B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005346577 2005-11-30

Publications (2)

Publication Number Publication Date
TW200730540A TW200730540A (en) 2007-08-16
TWI372152B true TWI372152B (en) 2012-09-11

Family

ID=38092236

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095144507A TWI372152B (en) 2005-11-30 2006-11-30 Novel peptide compounds

Country Status (18)

Country Link
US (4) US7939627B2 (zh)
EP (1) EP1961761B1 (zh)
JP (4) JP4394724B2 (zh)
KR (1) KR101385805B1 (zh)
CN (2) CN105315347A (zh)
AU (1) AU2006319892B2 (zh)
BR (1) BRPI0619255B8 (zh)
CA (1) CA2631292C (zh)
DE (1) DE602006017880D1 (zh)
DK (1) DK1961761T3 (zh)
ES (1) ES2352855T3 (zh)
HK (2) HK1122819A1 (zh)
PL (1) PL1961761T3 (zh)
PT (1) PT1961761E (zh)
RU (1) RU2424247C2 (zh)
SI (1) SI1961761T1 (zh)
TW (1) TWI372152B (zh)
WO (1) WO2007063903A1 (zh)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2378264T3 (es) 2003-11-05 2012-04-10 International Institute Of Cancer Immunology, Inc. Péptido antigénico de unión a HLA-DR derivado de WT1
EP1951281B1 (en) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
KR101385805B1 (ko) * 2005-11-30 2014-04-16 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 신규 펩티드 화합물
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
CN103103246B (zh) 2007-02-27 2018-05-01 株式会社癌免疫研究所 活化辅助t细胞的方法以及用于该方法的组合物
JP2011016751A (ja) * 2009-07-08 2011-01-27 Sumitomo Chemical Co Ltd 光学活性3−アミノピペリジン−1−カルボキシレート化合物の製造方法およびその製造方法に用いられる中間体
ES2708989T3 (es) 2010-03-31 2019-04-12 Stabilitech Biopharma Ltd Método de conservación de adyuvantes de alumbre y vacunas potenciadas con alumbre
GB2490644A (en) 2010-03-31 2012-11-07 Stabilitech Ltd Excipients for stabilising viral particles, polypeptides or biological material
WO2011121306A1 (en) 2010-03-31 2011-10-06 Stabilitech Ltd. Stabilisation of viral particles
WO2012046730A1 (ja) 2010-10-05 2012-04-12 国立大学法人大阪大学 ヘルパーt細胞の活性化方法
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
US9539299B2 (en) * 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
JP6163486B2 (ja) 2012-07-02 2017-07-12 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
CN104853764B (zh) * 2012-12-13 2018-06-22 海德堡吕布莱希特-卡尔斯大学 用于预防和治疗癌症的msi-特异性移码肽(fsp)
EP2933261B1 (en) 2012-12-17 2020-06-10 Otsuka Pharmaceutical Co., Ltd. Method for activating helper t cell
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
PT2945647T (pt) * 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
CA2840988A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for mucosal administration
RU2685933C2 (ru) 2013-02-05 2019-04-23 Нитто Денко Корпорейшн Композиция противораковой вакцины, содержащая пептид wt1, для трансдермального введения
JP6512569B2 (ja) 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用wt1ペプチド癌ワクチンテープ剤
KR20140100419A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 wt1 펩티드 암 백신 조성물
WO2014136814A1 (ja) * 2013-03-08 2014-09-12 大鵬薬品工業株式会社 新規ctlエピトープ5連結ペプチド
ES2694328T3 (es) 2013-03-12 2018-12-19 Sumitomo Dainippon Pharma Co., Ltd. Composición acuosa líquida
JP6671956B2 (ja) * 2013-03-29 2020-03-25 大日本住友製薬株式会社 Erap1によるトリミング機能をきっかけとしたコンジュゲートワクチン
MX364459B (es) * 2013-03-29 2019-04-26 Sumitomo Dainippon Pharma Co Ltd Vacuna de conjugado de péptido-antígeno de wt1.
ES2796301T3 (es) 2013-10-21 2020-11-26 Taiho Pharmaceutical Co Ltd Nuevo péptido con cuatro epítopos CTL unidos
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
ES2916834T3 (es) 2014-09-27 2022-07-06 Sumitomo Pharma Co Ltd Composición farmacéutica para inyección
JP6671141B2 (ja) * 2014-10-21 2020-03-25 大日本住友製薬株式会社 懸濁液剤
JP6699013B2 (ja) * 2014-12-25 2020-05-27 国立大学法人三重大学 Wt1由来ペプチド認識抗体
US20200016255A1 (en) 2016-11-30 2020-01-16 Sumitomo Dainippon Pharma Co., Ltd. Wt1 helper peptides and combinations of wt1 helper peptide and conjugate of cancer antigen peptides
JPWO2018181648A1 (ja) 2017-03-30 2020-02-13 大日本住友製薬株式会社 Wt1癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
CA3113212A1 (en) 2018-09-28 2020-04-02 Sumitomo Dainippon Pharma Co., Ltd. Injectable composition
MX2021003938A (es) 2018-10-05 2021-08-11 Int Inst Cancer Immunology Inc Composicion para prevenir o tratar un tumor benigno.
US20220241409A1 (en) 2019-04-05 2022-08-04 Sumitomo Dainippon Pharma Co., Ltd. Water soluble adjuvant and composition containing same
CN113966326A (zh) 2019-04-05 2022-01-21 大日本住友制药株式会社 水溶性佐剂
WO2021230247A1 (ja) 2020-05-12 2021-11-18 大日本住友製薬株式会社 癌を処置するための医薬組成物
JPWO2023017836A1 (zh) 2021-08-12 2023-02-16

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6297041B1 (en) * 1992-03-11 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6309642B1 (en) * 1997-04-28 2001-10-30 The Research And Development Institute, Inc. Peptides which mimic candida carbohydrate epitopes and their use in a vaccine
US5858682A (en) * 1996-08-02 1999-01-12 Pharmingen E2A/pbx1 fusion protein specific monoclonal antibodies
BRPI9912663B8 (pt) * 1998-07-31 2021-07-06 Int Inst Cancer Immunology Inc vacina contra cáncer e polipeptìdeo.
MY139226A (en) 1998-09-30 2009-08-28 Corixa Corp Compositions and methods for wt1 specific immunotherapy
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
TWI318630B (en) 2001-03-22 2009-12-21 Int Inst Cancer Immunology Inc Wt1 modified peptide
CN1306956C (zh) * 2001-04-17 2007-03-28 希龙公司 诱导功能活性抗体的脑膜炎球菌b抗原表位的分子模拟物
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
EP1447091A4 (en) 2001-09-28 2008-02-13 Institute Of Can International NEW METHOD FOR INDUCTION OF ANTIGEN SPECIFIC T CELLS
CN101113163B (zh) * 2002-06-12 2010-10-06 株式会社国际癌症免疫研究所 Hla-a24限制性癌抗原肽
WO2004024175A1 (ja) 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
ATE442378T1 (de) 2002-09-20 2009-09-15 Int Inst Cancer Immunology Inc Substituierte wt1-peptide
CN1735864A (zh) * 2003-01-13 2006-02-15 施克莱无线公司 主机可扩展无线应用接口
US20060217297A1 (en) 2003-01-15 2006-09-28 Haruo Sugiyama Dimerized peptide
KR101431312B1 (ko) * 2003-06-27 2014-08-20 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Wt1 백신 적응 환자의 선택 방법
ES2378264T3 (es) * 2003-11-05 2012-04-10 International Institute Of Cancer Immunology, Inc. Péptido antigénico de unión a HLA-DR derivado de WT1
EP1703887A4 (en) * 2003-12-31 2009-10-21 Univ Rochester IMMUNOGENIC POLYPEPTIDES AND CONJUGATES THAT CAN INDUCE ANTIBODIES AGAINST PATHOGENIC AGENTS AND USES THEREOF
ATE462003T1 (de) 2004-03-31 2010-04-15 Int Inst Cancer Immunology Inc Aus wt1 stammende krebsantigenpeptide
US7241580B2 (en) * 2004-06-08 2007-07-10 Wisconsin Alumni Research Foundation Immunoaffinity chromatography using epitope tags to polyol-responsive monoclonal antibodies
KR101385805B1 (ko) * 2005-11-30 2014-04-16 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 신규 펩티드 화합물

Also Published As

Publication number Publication date
US9273148B2 (en) 2016-03-01
DK1961761T3 (da) 2010-11-29
US8575308B2 (en) 2013-11-05
BRPI0619255B1 (pt) 2021-05-11
EP1961761A1 (en) 2008-08-27
ES2352855T3 (es) 2011-02-23
DE602006017880D1 (zh) 2010-12-09
CN101336249A (zh) 2008-12-31
PT1961761E (pt) 2010-12-16
US9765114B2 (en) 2017-09-19
JP5049323B2 (ja) 2012-10-17
EP1961761B1 (en) 2010-10-27
US7939627B2 (en) 2011-05-10
CA2631292A1 (en) 2007-06-07
EP1961761A4 (en) 2009-01-21
US20110229506A1 (en) 2011-09-22
BRPI0619255A2 (pt) 2011-09-27
BRPI0619255A8 (pt) 2015-12-15
JP4394724B2 (ja) 2010-01-06
JP2012158597A (ja) 2012-08-23
CA2631292C (en) 2014-05-06
AU2006319892A1 (en) 2007-06-07
HK1122819A1 (en) 2009-05-29
RU2008126305A (ru) 2010-01-10
JP5800928B2 (ja) 2015-10-28
AU2006319892B2 (en) 2012-05-10
KR101385805B1 (ko) 2014-04-16
KR20080073356A (ko) 2008-08-08
RU2424247C2 (ru) 2011-07-20
JP2009286792A (ja) 2009-12-10
WO2007063903A1 (ja) 2007-06-07
JP2014080435A (ja) 2014-05-08
JPWO2007063903A1 (ja) 2009-05-07
BRPI0619255B8 (pt) 2021-05-25
JP5597668B2 (ja) 2014-10-01
HK1221230A1 (zh) 2017-05-26
US20100062010A1 (en) 2010-03-11
PL1961761T3 (pl) 2011-04-29
US20160168197A1 (en) 2016-06-16
US20140046036A1 (en) 2014-02-13
CN105315347A (zh) 2016-02-10
TW200730540A (en) 2007-08-16
SI1961761T1 (sl) 2010-12-31

Similar Documents

Publication Publication Date Title
HK1221230A1 (zh) 新型肽化合物
GB0508863D0 (en) Peptide
AP2007004171A0 (en) Novel compounds
EP1868611A4 (en) NOVEL CONNECTIONS
GB0526019D0 (en) Peptides
EP1869026A4 (en) NEW CONNECTIONS
GB0516527D0 (en) Peptides
EP1939286A4 (en) NEW PEPTIDE
GB0500140D0 (en) Novel compounds
GB0509835D0 (en) Peptide
GB0516303D0 (en) Peptide
GB0523953D0 (en) Peptides
GB0512969D0 (en) Peptides
GB0500884D0 (en) Novel compounds
GB0503122D0 (en) Novel compounds
GB0500405D0 (en) Novel compounds
GB0500406D0 (en) Novel compounds
GB0500513D0 (en) Novel compounds
GB0500839D0 (en) Novel polyacetylen compounds
GB0500883D0 (en) Novel compounds
GB0500282D0 (en) Novel compounds
GB0500885D0 (en) Novel compounds
GB0500886D0 (en) Novel compounds
GB0500887D0 (en) Novel compounds
GB0500916D0 (en) Novel compounds